Menu
Currency
GWAS Study

Genome-wide association study of peripheral artery disease in the Million Veteran Program.

Klarin D, Lynch J, Aragam K et al.

31285632 PubMed ID
GWAS Study Type
637468 Participants
130 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

KD
Klarin D
LJ
Lynch J
AK
Aragam K
CM
Chaffin M
AT
Assimes TL
HJ
Huang J
LK
Lee KM
SQ
Shao Q
HJ
Huffman JE
NP
Natarajan P
AS
Arya S
SA
Small A
SY
Sun YV
VM
Vujkovic M
FM
Freiberg MS
WL
Wang L
CJ
Chen J
SD
Saleheen D
LJ
Lee JS
MD
Miller DR
RP
Reaven P
AP
Alba PR
PO
Patterson OV
DS
DuVall SL
BW
Boden WE
BJ
Beckman JA
GJ
Gaziano JM
CJ
Concato J
RD
Rader DJ
CK
Cho K
CK
Chang KM
WP
Wilson PWF
OC
O'Donnell CJ
KS
Kathiresan S
TP
Tsao PS
DS
Damrauer SM
Chapter II

Abstract

Summary of the research findings

Peripheral artery disease (PAD) is a leading cause of cardiovascular morbidity and mortality; however, the extent to which genetic factors increase risk for PAD is largely unknown. Using electronic health record data, we performed a genome-wide association study in the Million Veteran Program testing ~32 million DNA sequence variants with PAD (31,307 cases and 211,753 controls) across veterans of European, African and Hispanic ancestry. The results were replicated in an independent sample of 5,117 PAD cases and 389,291 controls from the UK Biobank. We identified 19 PAD loci, 18 of which have not been previously reported. Eleven of the 19 loci were associated with disease in three vascular beds (coronary, cerebral, peripheral), including LDLR, LPL and LPA, suggesting that therapeutic modulation of low-density lipoprotein cholesterol, the lipoprotein lipase pathway or circulating lipoprotein(a) may be efficacious for multiple atherosclerotic disease phenotypes. Conversely, four of the variants appeared to be specific for PAD, including F5 p.R506Q, highlighting the pathogenic role of thrombosis in the peripheral vascular bed and providing genetic support for Factor Xa inhibition as a therapeutic strategy for PAD. Our results highlight mechanistic similarities and differences among coronary, cerebral and peripheral atherosclerosis and provide therapeutic insights.

24,009 European ancestry cases, 150,983 European ancestry controls, 5,373 African ancestry cases, 42,485 African ancestry controls, 1,925 Hispanic cases, 18,285 Hispanic controls

Chapter III

Study Statistics

Key metrics and study information

637468
Total Participants
GWAS
Study Type
Yes
Replicated
5,117 European ancestry cases, 389,291 European ancestry controls
Replication Participants
European, African unspecified, Hispanic or Latin American
Ancestry
U.K., U.S.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.